Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy-induced cardiotoxicity.

Literature DB >> 22382639

Chemotherapy-induced cardiotoxicity.

Abstract

Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22382639 DOI： 10.1007/s11897-012-0083-y

Source DB: PubMed Journal: Curr Heart Fail Rep ISSN： 1546-9530

64 in total

1. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.

Authors: José A Tallaj; Verónica Franco; Barry K Rayburn; Laura Pinderski; Raymond L Benza; Salpy Pamboukian; Brian Foley; Robert C Bourge
Journal: J Heart Lung Transplant Date: 2005-12 Impact factor: 10.247

2. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Authors: J L Speyer; M D Green; A Zeleniuch-Jacquotte; J C Wernz; M Rey; J Sanger; E Kramer; V Ferrans; H Hochster; M Meyers
Journal: J Clin Oncol Date: 1992-01 Impact factor: 44.544

3. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

Authors: Geoffrey J Yoon; Melinda L Telli; David P Kao; Kelly Y Matsuda; Robert W Carlson; Ronald M Witteles
Journal: J Am Coll Cardiol Date: 2010-11-09 Impact factor: 24.094

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

5. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

Authors: Maria T Sandri; Michela Salvatici; Daniela Cardinale; Laura Zorzino; Rita Passerini; Paola Lentati; Maria Leon; Maurizio Civelli; Giovanni Martinelli; Carlo M Cipolla
Journal: Clin Chem Date: 2005-06-02 Impact factor: 8.327

Review 6. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

Authors: M I Gharib; A K Burnett
Journal: Eur J Heart Fail Date: 2002-06 Impact factor: 15.534

7. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

Authors: Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Valeriano C Simbre; Seema L Shaikh; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal: J Clin Oncol Date: 2002-12-01 Impact factor: 44.544

8. Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors: Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544

9. Doxorubicin-induced cardiomyopathy treated with carvedilol.

Authors: S Fazio; E A Palmieri; B Ferravante; F Bonè; B Biondi; L Saccà
Journal: Clin Cardiol Date: 1998-10 Impact factor: 2.882

10. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.

Authors: Z M Quezado; W H Wilson; R E Cunnion; M M Parker; D Reda; G Bryant; F P Ognibene
Journal: Ann Intern Med Date: 1993-01-01 Impact factor: 25.391

19 in total

Review 1. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer.

Authors: Kathleen M Sturgeon; Bonnie Ky; Joseph R Libonati; Kathryn H Schmitz
Journal: Breast Cancer Res Treat Date: 2013-12-14 Impact factor: 4.872

2. The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.

Authors: Sayantan Banerjee; Kuntal Halder; Sweta Ghosh; Anamika Bose; Subrata Majumdar
Journal: Oncoimmunology Date: 2015-01-30 Impact factor: 8.110

3. A Fluorescence Study of the Interaction of Anticancer Drug Molecule Doxorubicin Hydrochloride in Pluronic P123 and F127 Micelles.

Authors: Sagar Kumar Behera; Maneesha Esther Mohanty; Monalisa Mohapatra
Journal: J Fluoresc Date: 2020-10-10 Impact factor: 2.217

Chemotherapy-induced cardiotoxicity.

1. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.

2. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

3. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

5. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

Review 6. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

7. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

8. Cardiac dysfunction in the trastuzumab clinical trials experience.

9. Doxorubicin-induced cardiomyopathy treated with carvedilol.

10. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.

Review 1. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer.

2. The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.

3. A Fluorescence Study of the Interaction of Anticancer Drug Molecule Doxorubicin Hydrochloride in Pluronic P123 and F127 Micelles.

4. Fluorescence properties of doxorubicin in PBS buffer and PVA films.

5. Cardiotoxicity associated with targeted cancer therapies.

6. Gingerol-derivatives: emerging new therapy against human drug-resistant MCF-7.

Review 7. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.

Review 8. Cardiotoxicity in HER2-positive breast cancer patients.

9. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress.

Review 10. Intraoperative Hypotension Increased Risk in the Oncological Patient.